World news and discussion on TalkFuse.
Senate Commission Says China Is Seizing Drug Supply Chain, Pushes For Congressional Action
A US Senate commission says China is gaining influence over global drug and biopharmaceutical supply chains, and warns that deals between Western pharmaceutical companies and Chinese biotech firms could weaken US research and development. It is urging Congress to advance legislation intended to strengthen American biotechnology and speed up the path from research to market.
The commission analysed 57 deals made from early 2023 to October, involving investment and licensing agreements; AstraZeneca, Bristol Myers Squibb and Pfizer were among the companies cited. The proposed bipartisan National Biotechnology Safety Act, introduced by Senators Todd Young and Alex Padilla in September 2025, was referred to the Senate HELP Committee, with no further action reported. The commission says it would authorise $50 million from 2026 to 2030 for research and regulatory changes to help US biotech products reach the market sooner.
In short
- Senate commission warns China is gaining influence over drug supply chains.
- Its analysis reviewed 57 deals involving Western and Chinese biotech firms.
- Senators Young and Padilla’s proposed bill would authorise $50 million.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters argue that dependence on Chinese biotech and drug supply chains could leave the US exposed to disruption and allow valuable research or capabilities to shift abroad. They see targeted investment and faster regulatory pathways as a way to strengthen domestic innovation, protect public health and keep the US competitive, while the proposed funding is limited and the bill is bipartisan.
The case against
Sceptics could argue that commercial partnerships with Chinese biotech firms can bring investment, expertise and access to a large research ecosystem, and that evidence about 57 deals does not by itself show that US research or supply security is being weakened. They may also question whether new restrictions or subsidies are the best response, given the cost and risk of slowing beneficial collaboration or favouring domestic firms without clear evidence of public benefit.
Explained simply
Biotechnology uses living cells and biological processes to develop medicines and other products. Drug supply chains can span several countries, from early research and clinical trials to manufacturing and distribution, so companies often work with overseas partners through investment or licensing deals.
The US Senate commission examined 57 deals involving Western pharmaceutical companies and Chinese biotech firms, including companies such as AstraZeneca, Bristol Myers Squibb and Pfizer. Its concern is that partnerships could shift expertise or commercial opportunities abroad, affecting where future research and development takes place.
The National Biotechnology Safety Act is a bipartisan proposal from Senators Todd Young and Alex Padilla. It would provide $50 million from 2026 to 2030 for research and regulatory changes intended to help US biotechnology products reach the market sooner; it has been referred to the Senate HELP Committee.
Asia Government Health Medicine Politics World